L to R: Friedrich W. Gause, Dr. Seung Jun Oh, Jong Woo Kim During the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging in Philadelphia, representatives of Asan Medical Center, DuChemBio Co., Ltd. and BGM Associates GmbH inked a Licensing Consortium Agreement for the international partnering of the molecular imaging compound – [18F]-fluoroestradiol (FES). [18F]FES is a fluorine-18 labelled radiopharmaceutical used for the imaging of breast cancer patients with positron emission tomography (PET) cameras.
Asan Medical Center, one of the leading research hospitals in Asia-Pacific region, has recently finalized its phase III trial in Korea and is now seeking regulatory approval for the [18F]FES from Korean Health Authorities.
DuChemBio, the leading radiopharmaceutical company in Korea, alongside BGM Associates are now in charge of the international partnering and development of the breast cancer radiopharmaceutical.
Asan Medical Center, one of the leading research hospitals in Asia-Pacific region, has recently finalized its phase III trial in Korea and is now seeking regulatory approval for the [18F]FES from Korean Health Authorities.
DuChemBio, the leading radiopharmaceutical company in Korea, alongside BGM Associates are now in charge of the international partnering and development of the breast cancer radiopharmaceutical.
